about
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsComplement in monoclonal antibody therapy of cancerAn Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or NeuregulinDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionTwenty years of anti-HER2 therapy-associated cardiotoxicitySuppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy"Identification of novel drugs to target dormant micrometastasesChemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionA phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patientThe HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathwayFoxM1 mediates resistance to herceptin and paclitaxel.Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.Alpha-actinin 4 and tumorigenesis of breast cancer.Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.The war on cancer: lessons from the war on terrorPrimary trastuzumab resistance: new tricks for an old drug.Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumabMonoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies.Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsAssociation of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapyAn integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancerHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics.The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with HerceptinHER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Investigating the photosensitizer-potential of targeted gallium corrole using multimode optical imaging.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerProspective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant.
P2860
Q26753162-2AB254BD-B188-4431-A95B-4537B70F864EQ26772969-BB3F6E1E-441F-44CA-81FB-E4EC4AED9A4CQ26852287-817AEB9B-89BB-4422-BDDD-43F41AB9E4E6Q26860800-EFBBC382-8393-4716-9011-CCE972178978Q27679463-B50DC6B8-1903-49C4-8F60-1F18071BD8BFQ27851628-5BEBEC69-31BA-4CE7-A8ED-433535C76A55Q28067145-F8B5E9AD-705D-45A8-B731-89EF5AAE249BQ28079391-B18E9767-2C30-4995-8515-8525003EE0C8Q28383446-6D9C20E8-F684-4A40-A5C1-A1E0747E2FD0Q28394296-745E663C-4793-4608-9EC6-CEA42ACD89A8Q30399577-099D6191-628E-4CAE-8EB0-D2BEBC165D0CQ33629947-75B306DC-1C8A-4337-8F3E-9875E3B7A64FQ33649880-3DDFDB40-3FBE-40A2-9875-AA42B8DBFC02Q33661325-C73061AD-8D36-4B8B-B728-7B1EC98C2377Q33728102-A8FD885D-FE6A-461D-8641-F0A3A1F2AE1EQ33769034-2E1D306E-9A7D-4CFA-93A9-E5BFAE46E055Q33777431-FC7D5902-2202-4491-AE7E-12AD3897F429Q33880386-1B916404-5647-4F2D-87F7-EFFF7C6FCF56Q33946664-F2A5BBC8-C0BC-4B74-A81B-CA1FA522DF28Q34009045-1CF01D6D-AF22-4D51-AE8E-C02B32AA4D2CQ34084701-4669BB79-084E-4100-9F38-1E84BC64BCACQ34318275-B140F830-85DD-4875-88EC-8BD6D904C9BFQ34368669-2486F9CD-FC32-489B-8CA9-FEB1FEFC8A28Q34610251-02DC1575-7F93-43C6-BCDB-EFD192E70BCFQ34621713-165CE7C9-9C8D-4C46-9C2F-BD2FEF6610FEQ34662933-594DD77E-2F87-47AE-9345-DFFCCC7E2E2CQ34687047-68B359B4-0E0D-4188-9E5E-E639EF5DAA30Q34714574-FD19545A-43A8-469E-A41A-0C355DABDEA9Q34760876-DA20AC49-5675-4E17-9964-707E2EBDA2D4Q34776985-B9DD91C3-19EF-4A97-AA72-683A94E31FC9Q34974436-5EFF6969-27F5-4F35-A6F5-B051FC0F17ADQ34996222-2BEABA05-10B7-4BA6-ADCB-A5E79676A14BQ34998307-2382CA6F-91EB-4B8B-A8C3-1BE30451235FQ35068522-A056039D-1260-4B23-A0F6-C2D620ADE869Q35184360-986966FE-4B15-4882-8E51-0E095AC66A88Q35235832-A0E306FC-2378-4FEF-9E9D-6DCE03174D23Q35652606-65015D53-3547-4EFB-8865-B4E5A6FA2F07Q35684440-DD7C0939-96FD-4E65-AD54-E82EA6A484AEQ35689902-3C57D764-A527-4B8D-A43F-D6E93AB66508Q35733827-CD925F21-17FB-4744-B109-05A828F0D2D6
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Resistance to Trastuzumab in Breast Cancer.
@ast
Resistance to Trastuzumab in Breast Cancer.
@en
type
label
Resistance to Trastuzumab in Breast Cancer.
@ast
Resistance to Trastuzumab in Breast Cancer.
@en
prefLabel
Resistance to Trastuzumab in Breast Cancer.
@ast
Resistance to Trastuzumab in Breast Cancer.
@en
P2860
P1476
Resistance to Trastuzumab in Breast Cancer
@en
P2093
Ingrid A Mayer
Ray Mernaugh
P2860
P304
P356
10.1158/1078-0432.CCR-09-0636
P407
P577
2009-12-01T00:00:00Z